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Abstract: 
 
Background: The “GENetIcs of sUbSequent Coronary Heart Disease” (GENIUS-CHD) 
consortium was established to facilitate discovery and validation of genetic variants and 
biomarkers for risk of subsequent CHD events, in individuals with established CHD.  
Methods: The consortium currently includes 57 studies from 18 countries, recruiting 185,614 
participants with either acute coronary syndrome, stable CHD or a mixture of both at baseline.  
All studies collected biological samples and followed-up study participants prospectively for 
subsequent events.  
Results: Enrolment into the individual studies took place between 1985 to present day with 
duration of follow up ranging from 9 months to 15 years. Within each study, participants with 
CHD are predominantly of self-reported European descent (38%-100%), mostly male (44%-
91%) with mean ages at recruitment ranging from 40 to 75 years. Initial feasibility analyses, 
using a federated analysis approach, yielded expected associations between age (HR 1.15 95% 
CI 1.14-1.16) per 5-year increase, male sex (HR 1.17, 95% CI 1.13-1.21) and smoking (HR 1.43, 
95% CI 1.35-1.51) with risk of subsequent CHD death or myocardial infarction, and differing 
associations with other individual and composite cardiovascular endpoints.   
Conclusions: GENIUS-CHD is a global collaboration seeking to elucidate genetic and non-
genetic determinants of subsequent event risk in individuals with established CHD, in order to 
improve residual risk prediction and identify novel drug targets for secondary prevention. Initial 
analyses demonstrate the feasibility and reliability of a federated analysis approach.  The 
consortium now plans to initiate and test novel hypotheses as well as supporting replication and 
validation analyses for other investigators.  
 
 
 
 
 
 
Key words: coronary artery disease; genetics, association studies; residual risk; secondary 
prevention; recurrent event; myocardial infarction; prognosis 
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Introduction 
Major public health initiatives and policy changes, along with advances in drug and 
interventional therapies have significantly reduced cardiovascular morbidity and mortality in 
most high-income countries.1-3 However, the improved survival rates following an initial 
presentation with coronary heart disease (CHD) has, paradoxically, led to a growing number of 
patients living with established CHD (e.g 16M in the USA, 3M in the UK)4 5 who remain at 
substantially high risk of subsequent cardiovascular events. These include myocardial infarction 
(MI), repeated revascularizations, but also heart failure (HF), stroke and sudden death.4  
Despite a large body of knowledge on the pathophysiology of first CHD events in general 
populations,6, 7 little is known about factors that influence disease progression or subsequent 
events in patients with established CHD, beyond those consequent to the acute index event in the 
short term (such as biomarkers of myocardial dysfunction or necrosis, left ventricular function or 
arrhythmia).8  As a result, although guidelines and treatment thresholds have progressively 
evolved over the last two decades, the targeted risk factors per se have remained largely 
unaltered.9 Novel therapies beyond lipid lowering, anti-platelet agents, and drugs recommended 
for high blood pressure and heart failure have been slow to emerge.  Importantly, multiple novel 
and existing agents (e.g darapladib, varespladib, , and folic acid) have failed in very late stage 
clinical development despite promising observational data.10, 11 12, 13  In contrast, some traditional 
risk factors, such as obesity, which show robust associations with initial CHD onset,14 continue 
to show inverse or null associations with subsequent events once CHD has developed.15  
Ultimately, the high (residual) risk in individuals with existing CHD despite optimal 
contemporary therapy emphasizes the need for studying risk of subsequent events and their 
related causal pathways. For example, in the intervention arm of the IMPROVE-It study, despite 
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simvastatin and ezetimibe treatment following an acute coronary syndrome, at 7 years, almost a 
third of participants experienced the primary endpoint (a composite of cardiovascular death, 
major coronary event, coronary revascularization or nonfatal stroke).16 Similarly, in the 
FOURIER trial, almost 10% of patients with established but stable CVD, experienced an event at 
2.2 years despite high intensity statin and PCSK9 inhibition, with achieved median LDL-C levels 
of 30mg/dL.17 These data point to the existence of risk factors beyond traditional ones such as 
LDL-C, and the need to elucidate their related causal pathways.18 By studying those with 
established CHD at high risk of subsequent events, we plan to gain novel insights into other 
drivers of atherosclerosis or features that identify patients who may benefit most from novel 
therapies.9  Genetic and biomarker studies in these individuals may help identify novel molecular 
pathways and future drug targets with the goal of advancing precision medicine.  
In the absence of a single large resource to study the determinants of coronary heart 
disease prognosis , we have established The GENetIcs of SUbSequent CHD (GENIUS-CHD) 
consortium.19 Assembling studies from across the globe that have recruited patients with 
different types of CHD at baseline, have acquired prospective follow up, and have stored 
biological specimens, or genetic data, the consortium aims to: (1) investigate genetic and non-
genetic determinants of risk for subsequent CHD, systematically and at scale; and (2) facilitate 
access to data and expertise, as a platform to foster collaboration among investigators working in 
the field.  
Here we describe the design of the consortium, including details of participating studies, 
available data and samples, as well as the governance procedures and the consortium’s approach 
to data sharing and collaboration to further advance the stated scientific aims.  In addition, we 
present some early findings from an investigation of the association of patient characteristics and 
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certain routinely recorded measures on the risk of subsequent events among patients with 
different types of CHD at baseline.  
 
Methods  
In accordance with Transparency and Openness Promotion (TOP) Guidelines, the data, analytic 
methods, and study materials will be made available to other researchers for purposes of 
reproducing the results or replicating the procedures. Participating studies received local 
institutional review board approval and included patients who had provided informed consent at 
the time of enrolment. The central analysis sites also received waivers from their local 
institutional review board for collating and analysing summary level data from these individual 
studies. Full details on the eligibility criteria, definitions of terminology, management of the 
consortium, and planned projects are provided in Supplementary Materials. 
 
Results 
The design and structure of the GENIUS-CHD consortium is presented in Figure 1. Studies 
meeting the main eligibility criteria were identified and invited to participate (Supplementary 
Methods). In brief, studies are eligible to join the GENIUS-CHD consortium if they meet three 
inclusion criteria: (1) included individuals with established CHD (defined as the presence of or 
confirmed history of acute coronary syndrome at baseline, or of coronary artery disease as 
evidenced by any revascularization procedure (percutaneous coronary intervention or bypass 
surgery) or demonstrable plaque in any epicardial vessel on direct coronary imaging); (2) 
acquired prospective follow-up of participants with ascertainment of one or more subsequent 
cardiovascular disease events as well as all-cause mortality; and, (3) had stored blood samples, 
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which are viable and suitable for DNA and/or biomarker analysis or previously collected such 
data prior to sample depletion.    
At the time of writing, 57 studies from 18 countries are participating in the consortium 
and are listed in Table 1.  Please refer to www.genius-chd.org for an updated list. Brief narrative 
descriptions of each study are provided in Supplementary Methods.   
The majority of studies are either investigator-led clinical cohorts (n=42), but clinical 
trials (n=10) and nested case cohort (inception-study design) studies (n=5) are also included. Of 
the total, 23 studies have included participants at the time of an ACS, while the remainder 
recruited those with stable CHD or a mixture of the two (e.g. from cardiac catheterization labs).  
Collectively, 185,614 participants have been enrolled with CHD at baseline (including 812,803 
person years of follow-up); of which 170,343 are of self-reported European descent. Recruitment 
times varied between studies, ranging from the earliest recruitment in 1985 to studies that remain 
actively recruiting to the present day.  All studies enrolled patients >18 years of age, although 
one study exclusively recruited only those with premature CHD (MI<45 years), while another 
recruited only older subjects (>70 years). The overall mean age within each study reflects this 
heterogeneity, ranging from 40-75 years of age, and proportion of male sex ranging from 44-
91% (Table 1). 
Available data: 
Core phenotypes: All studies collected data on age, sex and ethnicity. Risk factor data are 
available for diabetes, obesity and smoking status in almost all participating studies (96%), while 
data on concentrations of routine blood lipids (total cholesterol, LDL-C, HDL-C and 
triglycerides) (84%) and blood pressure values at enrolment (82%) were collected by the 
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majority of studies.  Data on statin use at baseline are available in 90% of all participating studies 
(Table 2).  
Additional phenotypes: A list of selected additional phenotypes available by study is presented 
in Supplementary Table 1.  Of note, 79% have available data on plasma C-Reactive Protein 
(CRP), while coronary disease burden information, from invasive angiography is available in 
52% of studies. Finally, over a third of studies have also collected data on physical activity 
(38%) and socioeconomic status (37%).  
Samples: Stored samples are available in most studies for future assay testing and stored frozen. 
The majority have stored plasma (75%), while others also have serum, blood EDTA, RNA and 
urine (Supplementary Table 2). 
DNA & Genotyping: More than two thirds of the studies have DNA still available, either pre-
extracted or as whole blood collected in EDTA and stored for future genotyping.  All studies 
within the consortium have performed genotyping in some capacity, with genome-wide data 
available in a subset of studies (Supplementary Table 3). 
Subsequent Events & Follow up: The most commonly collected endpoint was all-cause death, 
collected by all but two studies.  CHD death during follow up was collected in 70% of studies, 
while incident MI was reported by 82% of studies. Studies ascertained endpoints through 
different means, including telephone contact, in-person patient interviews, clinical chart reviews 
and linkage to national mortality registers and hospital records (Supplementary Table 4).  
Power Calculations 
Empirical power was estimated based on a conservative sample size of 150,000 subjects with an 
event rate of 10% (across the entire follow-up period with a mean of about five years); Figure 2. 
Given that the GENIUS-CHD consortium is designed to answer multiple questions, power was 
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estimated for a range of genetic (SNPs) and non-genetic (biomarkers, clinical risk factors) 
effects. 
Minor allele frequencies (MAF) of 0.01, 0.05, 0.10 and 0.25 were examined, representing 
rare to common SNPs. For each MAF, power was calculated for a range of plausible SNP effects 
on biomarkers (mean difference (ߤ) 0.01, 0.03, 0.05) and clinical endpoints (odds ratios (ORs) of 
1.02, 1.05, 1.10). For the association of SNPs with biomarkers, power was 80% (alpha=0.05) or 
more unless the SNP was rare (MAF of 0.01) or the effect size was small (e.g., 0.01 per allele). 
For the association of SNPs with clinical endpoints, power was close to 80% when the effect size 
was large (OR ≥ 1.10) or the MAF was ≥ 0.10.  
Power of observational (i.e. non-genetic) analysis was >99% for both continuous and 
binary exposures unless the OR was close to 1. In addition to continuous and binary outcome 
data, GENIUS-CHD also collects time-to-event data. Given the similarity (in most empirical 
settings) between OR and hazard ratios,20 similar power is to be expected for time-to-event 
analysis.  
Initial Analysis: 
To examine the feasibility of the federated analysis approach, we sought to collect data on 
participant characteristics, cardiovascular and mortality outcomes and association analyses with 
common clinical exposures.   A standardised dataset was developed, with a federated analysis 
conducted using standardised statistical scripts.  The summary level outputs generated were then 
shared with the coordinating centres for aggregating and meta-analysis (Supplementary 
Methods).    
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Participant characteristics 
Detailed characteristics of participants by study are presented in Table 2.  Prevalence of risk 
factors varied by study, with diabetes ranging from 4 to 76%; smoking from 8 to 79%. Mean 
total cholesterol by study ranged from 166.3 to 239.8 mg/dL, mean BMI ranged from 24.8 to 
30.2kg/m2   and mean systolic blood pressure from 117 to 153mmHg. The proportion of 
participants with prior revascularization or MI was high in most studies reflecting the inclusion 
criteria for the consortium (Table 2). 
Review of returned outputs from the federated analysis revealed good quality data with 
estimates falling within expected ranges for age, sex, and other variables such as body mass 
index (Supplementary Figure 1).  
Endpoints 
The primary endpoint pre-selected for the study was a composite of coronary death or MI (CHD 
death/MI).  Mean follow up was estimated in each study and ranged between 9 months and 15 
years. In total we estimated over 748,000 person years of follow up were available for the 
primary endpoint analysis. 
Information was collected on 10 subsequent event endpoints in the initial feasibility 
analysis.  Across all studies, the most frequently occurring event during prospective follow up 
was the composite of all cardiovascular events (27%); followed by revascularization (21.8%); 
all-cause mortality (15%); coronary death or MI (14.2%); myocardial infarction (10.7%); 
cardiovascular death (8.3%); coronary death (8%); heart failure (6.3%); all stroke (3.6%) and 
ischaemic stroke (3.4%).  
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Association analyses:  
As a feasibility analysis, we examined associations between age, male sex and smoking with the 
primary endpoint CHD death/MI as well as with the nine other secondary endpoints, to 
investigate any differential associations across discrete subsequent events.   
In analyses unrestricted by race or type of CHD at baseline, but adjusted for sex, there 
was a strong association between each 5-year increment in age with subsequent risk of the 
primary endpoint of CHD death/MI (HR 1.15, 95% CI 1.14-1.16).  The largest observed hazard 
ratios were for all-cause mortality (HR 1.36, 95% CI 1.35-1.37), cardiovascular death (HR 1.36, 
95% C.I. 1.35, 1.38) and heart failure (HR 1.25, 95% CI 1.24, 1.27), while a smaller risk increase 
was observed for MI (HR 1.06, 95% CI 1.05-1.07).  The risk of future revascularization, 
however, showed a modest inverse association with increasing age (HR 0.98, 95% CI 0.98-0.99) 
(Figure 3). 
Male sex was a risk factor for CHD death/MI (HR 1.17, 95% CI 1.13- 1.21) and other 
coronary and mortality endpoints (Figure 4) after adjustment for age. In particular, the largest 
observed hazard ratio was for risk of revascularization, which was considerably higher in males 
(HR 1.24, 95% C.I. 1.20, 1.27). In contrast, there was no strong evidence for an association 
between male sex and risk of stroke (ischemic or any stroke, Figure 4).  
Finally, in analyses adjusted for age and sex, current smoking (compared to prior or never 
smoking) at the time of enrolment showed a strong association with risk of future CHD death/MI 
(HR 1.43, 95% C.I. 1.35-1.51). Similarly, smoking was associated with an increased risk of all-
cause mortality (HR 1.53, 95%CI 1.47-1.58) and an increased risk of all other end points, 
although there was no strong evidence for an association with incident revascularization (HR 
1.02, 95% CI 0.99-1.05, Figure 5). 
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When stratified by type of CHD at enrolment, i.e. among those presenting with an acute 
event, those with stable CAD without ever having had an MI and those with stable CAD and a 
prior MI, the findings were similar and directionally concordant to non-stratified analyses 
described above, for all endpoints (data not shown). 
 
Discussion 
The GENIUS-CHD Consortium is a global collaborative effort engaging 57 studies, including 
almost 185,000 patients with established CHD, for whom genetic and prospective follow-up data 
are available. It brings together over 170 domain experts, including clinicians, data scientists, 
geneticists and epidemiologists, all engaged in improving our understanding of the determinants 
of subsequent event risk in these patients.  With an agreed governance structure and a proven 
federated analysis approach, we anticipate that this consortium will be a valuable long-term 
resource for genetic and non-genetic research in this field.   
Genetic association studies for CHD disease progression, recurrence and adverse events 
after a CHD event may have particular utility for identifying novel causal pathways and 
therapeutic targets that may be different than those for first events, a concept recently supported 
by research in other disease areas.21  However, information on the determinants of subsequent 
CHD event risk is scarce, in contrast to the extensive knowledge about risk factors for a first 
CHD event. This disparity is due in part to the relatively small sample sizes of individual studies 
in the secondary prevention setting.  While larger registry and electronic health care records 
(EHR) efforts will result in higher numbers, they typically suffer from the lack of necessary 
depth of phenotyping, accuracy, and availability of bio-specimens to infer further biological 
insights.22, 23 In contrast, large population studies with detailed phenotyping have relatively small 
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numbers of mostly stable CHD patients, who have survived many years after their index event.24, 
25  By bringing together multiple investigator-led studies, the GENIUS-CHD consortium aims to 
address and overcome this major limitation to subsequent CHD risk research. 
Importantly, the scale and depth of the GENIUS-CHD consortium offers greater scope to 
tackle key challenges within subsequent CHD risk-related research.  Firstly, CHD is a 
heterogeneous phenotype, consisting of stable, unstable and pathologically distinct subtypes, 
which have often been combined for individual studies to satisfy the need for statistical power.  
With the sample size available in GENIUS-CHD, we anticipate being able to disaggregate CHD 
into more precise sub-phenotypes such as acute vs. stable CHD at baseline, or those with vs. 
without prior MI, which may help uncover relevant biological differences.26  Additional 
stratification on variables such as sex, time period of recruitment, duration of follow-up, country 
of study, LV function and treatment (such as statin, blood pressure lowering and anti-platelet 
agent use) will also be possible, providing greater insights into the modifying influences of these 
variables on outcome.   
A major strength of the consortium is the use of a federated analysis approach that 
permits individual level analysis without the need for sharing either samples or the individual 
datasets themselves, thereby overcoming major privacy and governance hurdles.  The effort has 
been successful because (1) participation is entirely voluntary, with studies only participating in 
those analyses they feel are of value, or to which they have the capacity to contribute; (2) 
ownership of all data and samples remain with the PI and are not shared nor stored centrally; and 
(3) there are open and transparent governance procedures. Our feasibility analysis has 
demonstrated that this federated approach works well and yields results that are consistent and 
suitable for high quality meta-analysis.  
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Indeed, supported by this initial feasibility analysis, our findings demonstrate the validity 
of the data collected by confirming the anticipated associations of increasing age, male sex, and 
current smoking with higher risks of subsequent CHD death/MI during follow up. Furthermore, 
by exploring multiple individual and composite endpoints, we can begin to unravel associations 
not discoverable in smaller studies.  For example, we find that the risk of incident 
revascularization is lower with advancing age but higher for male sex and neutral for smoking.  
Plausible explanations may exist for each of these findings (e.g. an association induced by 
clinical practice, with fewer older people being offered invasive treatments), but importantly they 
highlight the value of exploring multiple endpoints at appropriate scale.  This is especially 
relevant when exploring novel biomarkers or drug targets as these may, in turn be used to inform 
clinical testing strategies and choice of endpoints to study in trials. 
By virtue of the expertise it has assembled, the consortium is also well placed to address 
important methodological issues surrounding prognosis research in general.  For example, 
selection bias is a key concern, whereby it is conceivable that those at highest risk may die early 
and not enter any of the member studies for evaluation (survival bias), or selection on an 
indexing event itself may distort patient characteristics and impact association findings (index 
event bias).27  In addition, treatment effects may alter the trajectory of disease by stabilizing or 
regressing plaque burden or altering baseline risk, such as with high dose statin or PCSK9 
inhibitor use.17, 28 To address these and other issues, the consortium has established working 
groups of relevant national and international experts to explore the extent and impact of such 
biases/effects and if needed, to develop approaches to address these.29 
 There are inherent challenges to overcome when working with diverse multiple studies, 
including variations in definitions and processes for data collection and curation across different 
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studies in different centres and different countries. The consortium members have attempted to 
standardize common data elements, for example the measurement units for quantitative traits.  
Variability between studies will persist, but we anticipate that the overall size of the effort will 
help reduce the impact of such study level heterogeneity on any findings, which will also be 
explored through subgroup analyses where possible (e.g. country, study size, year of first 
recruitment).  Analytical challenges will additionally include dealing with variability in length of 
follow up across studies, handling multiple subsequent events along with competing risks, as 
well as confounding by treatment and selection biases as described above.  The collective 
experience of the consortium members will be leveraged to address these as carefully as possible 
within each future analysis.  Finally, factors influencing enrolment into genetic studies of CHD 
may limit the generalizability of findings. Men are over represented in participating CHD 
studies, partly reflecting sex-differential prevalence of disease but also underpinning a wider 
concern about under-investigation of women, who may be inadvertently excluded given that 
entry criteria for most studies relies on documented presence of CHD.  Similarly, many studies 
in the consortium have recruited mostly Europeans, limiting the opportunity to explore 
hypotheses in other ethnic groups.  The steering committee is conscious of these imbalances and 
is actively seeking studies enriched for women and non-European participants to join the 
collaboration.  In summary, the GENIUS-CHD consortium is a global collaboration among 
investigators who have recruited patients with CHD into multiple individual studies, seeking to 
gain a better understanding of subsequent CHD event risk and enhance secondary prevention.  It 
seeks to be an open, collegiate and transparent effort and we invite investigators with suitable 
studies to join and collectively enhance research efforts in this domain. 
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Table 1: Overview of each study participating in the GENIUS-CHD consortium  
 
Alias  Cohort Name Country Study Design Recruitment 
Period 
CHD 
Type 
Total 
recruited 
with CHD 
European 
ancestry 
(%) 
Europeans 
recruited 
with CHD 
Mean 
Follow up 
Time (SD) 
Age (SD) Male (%) PubMED ID 
4C Clinical Cohorts in Coronary disease Collaboration 
(4C) 
UK Clinical Cohort 2009-2014 CAD 3345 54.8 1832  2.56 (0.95) 61.8 (12.14) 61.5 NA 
AGNES Arrhythmia Genetics in The Netherlands Netherlands Clinical Cohort 2001-2005 ACS 1459 100.0 1459  6.73 (4.75) 57.8 (10.73) 79.2 20622880 
ANGES Angiography and Genes Study Finland Clinical Cohort 2002-2005 Mixed  588 100.0 588  8.20 (4.47) 64.1 (9.59) 65.5 21640993 
ATVB Italian Atherosclerosis, Thrombosis and Vascular 
Biology Group 
Italy Clinical Cohort 1997-2006 ACS  1741 100.0 1741 10.47 (4.45) 40.0 (4.40) 90.8 21757122 
CABGenomics CABG Genomics USA Clinical Cohort 2001-2014 Mixed  2694 85.5 2303 6.9 (3.5) 64.4 (10.38) 79 25649697 
CARDIOLINES CardioLines Netherlands Clinical Cohort 2011- Mixed  1269 75.0 1,692 1.3 (0.5) 63.5 (11.6) 72.8 NA 
CDCS Coronary Disease Cohort Study New Zealand Clinical Cohort 2002-2009 ACS  2139 91.4 1956  5.21 (2.15) 67.4 (12.01) 71.3 20400779 
COGEN The Copenhagen Cardiovascular Genetic study Denmark Clinical Cohort 2011-2017 Mixed  3709 95.0 3,904 5.5 (1.01) 70.1 (17.4) 67.5 In press 
COROGENE Corogene Study Finland Clinical Cohort 2006-2008 ACS 1489 100.0 1489 7.7 (0.5) 64.7 (11.88) 70.9 21642350 
CTMM Circulating Cells The 
Netherlands 
Clinical Cohort 2009-2011 Mixed  713 96.5 688  0.97 (0.37) 62.6 (10.08) 69 23975238 
CURE Cure-Genetics Study Canada RCT 1998-2000 ACS  12434 82.1 10203  0.78 (0.28) 65.4 (11.19) 61.4 11102254 
EGCUT Estonian Biobank Estonia Population 2002-2011 CAD 2783 100.0 2783  6.65 (2.93) 66.6 (10.99) 51.5 24518929 
EMORY Emory Cardiovascular Biobank USA Clinical Cohort 2004- Mixed  5873 72.0 4229  4.49 (3.15) 65.4 (11.74) 68.7 20729229 
ERICO Estratégia de Registro de Insuficiência Coronariana Brazil Clinical Cohort 2009-2014 ACS  738 61.0 450  2.85 (1.48) 63.8 (13.35) 56 23644870 
FASTMI2005 The French Registry of Acute ST elevation MI  France Clinical Cohort 2005- ACS 3669 100.0 3669  1.72 (0.63) 67.3 (13.94) 68.5 17893635 
FINCAVAS Finnish Cardiovascular Study Finland Clinical Cohort 2001-2008 Mixed  1671 100.0 1671  8.57 (3.99) 60.9 (11.04) 69.4 16515696 
FRISCII FRISCII Study Sweden RCT 1996-1998 ACS  3147 99.3 3125  7.46 (2.09) 66.3 (9.82) 69.5 10475181 
GENDEMIP GENetic DEtermination of Myocardial Infarction in 
Prague 
Czech 
Republic 
Clinical Cohort 2006-2009 ACS 1302 100.0 1302  1.13 (0.78) 56.5 (8.66) 74.4 23249639 
GENEBANK Cleveland Clinic Genebank Study USA Clinical Cohort 2001-2007 Mixed  2345 100.0 2345  3.00 (0.00) 61.5 (11.06) 74.3 21475195 
GENESIS-PRAXY GENdEr and Sex determInantS of cardiovascular 
disease: From bench to beyond-Premature Acute 
Coronary Syndrome (GENESIS-PRAXY) 
Canada Clinical Cohort 2009-2013 ACS  784 99.4 779  1.00 (0.00) 48.3 (5.62) 69.1 22607849 
GENOCOR Genetic Mapping for Assessment of Cardiovascular 
Risk 
Italy Clinical Cohort 2007-2010 Mixed  497 100.0 497  5.68 (1.20) 65.2 (8.47) 86.7 22717531 
GEVAMI The GEnetic causes to Ventricular Arrhythmia in 
patients during first ST-elevation Myocardial 
Infraction 
Denmark Clinical Cohort 2011- ACS 1033 100.0 1033 3.93 (1.40) 59.5 (10.37) 79.3 25559012 
GoDARTS incident Genetics of Diabetes Audit and Research in Tayside 
Scotland (I) 
Scotland Population 2004 - 2012 CAD 1261 99.8 1258  3.47 (2.95) 71.3 (10.91) 61.1 29025058 
GoDARTS prevalent Genetics of Diabetes Audit and Research in Tayside 
Scotland (P) 
Scotland Population 2004 - 2012 CAD 2514 99.7 2507  6.48 (3.06) 69.1 (9.41) 65.9 29025058 
GRACE_B Global Registry of Acute Coronary Events - 
Belgium 
Belgium Clinical Cohort 1999-2010 ACS  734 100.0 734  4.25 (1.80) 65.9 (11.91) 75.8 20231156 
GRACE_UK Global Registry of Acute Coronary Events - UK UK Clinical Cohort 2001-2010 ACS 1443 100.0 1443  9.54 (2.68) 64.3 (12.21) 69.6 20231156 
IDEAL Incremental Decrease in End Points Through 
Aggressive lipid Lowering (IDEAL) 
Canada RCT 1999-2005 ACS 8888 99.3 8823  4.63 (0.82) 61.8 (9.47) 80.8 16287954 
INTERMOUNTAIN Intermountain Heart Collaborative Study USA Clinical Cohort 1993-2009 Mixed  7556 89.5 6763  8.56 (5.39) 61.2 (11.06) 66.7 20691829 
INVEST INternational VErapamil SR Trandolopril STudy 
GENEtic Substudy INVEST-GENES 
USA/ 
International 
RCT  1997-2003 CAD  5979 38.0 2270 2.83 (0.82) 66.1 (9.70) 44 21372283, 
17700361 
JUMC Krakow-GENIUS-CHD Poland Clinical Cohort 2010-2014 Mixed  747 100.0 747  0.84 (0.34) 68.3 (10.26) 71.6 28444280, 
27481134 
KAROLA Karola Study Germany Clinical Cohort 1999-2000 Mixed  1206 100.0 1206 11.62 (3.01) 58.7 (8.15) 84.2 24829374 
LIFE-Heart Leipzig (LIFE) Heart Study Germany Clinical Cohort 2006-2014 Mixed  5564 100.0 5564  1.62 (2.03) 63.9 (11.09) 77.2 22216169 
LURIC The LUdwigshafen RIsk and Cardiovascular Health 
Study 
Germany Clinical Cohort 1997-2000 Mixed  2320 100.00 2320  8.58 (3.18) 63.8 (9.92) 76.6 11258203 
MDCS Malmo Diet and Cancer Study Sweden Population 1991-1996 CAD 4,546 100.00 4,546 8.3 (8.0) 58.0 (7.6) 60.2 19936945 
NE_POLAND North East Poland Myocardial Infarction Study Poland Clinical Cohort 2001-2005 ACS 646 100.0 646  7.20 (2.75) 62.3 (11.84) 75.4 26086777 
NEAPOLIS Neapolis Campania Italia Italy Clinical Cohort 2008-2012 Mixed  1394 100.0 1394  1.07 (0.54) 67.6 (10.50) 74.5 24262617 
OHGS Ottawa Heart Genomics Study Canada Clinical Cohort 2010-2013 Mixed  546 100.0 546  1.77 (0.27) 65.6 (11.11) 73.8 NA 
PERGENE Perindopril Genetic Association Study (EUROPA) Netherlands RCT 1997-2000 CAD 8746 99.0 8656  4.20 (0.62) 59.9 (9.27) 85.6 19082699 
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Alias  Cohort Name Country Study Design Recruitment 
Period 
CHD 
Type 
Total 
recruited 
with CHD 
European 
ancestry 
(%) 
Europeans 
recruited 
with CHD 
Mean 
Follow up 
Time (SD) 
Age (SD) Male (%) PubMED ID 
PLATO The Study of Platelet Inhibition and Patient 
Outcomes  
International RCT  2006-2008 ACS  18624 98.3 18315  0.86 (0.24) 62.6 (10.96) 69.5 19332184 
PMI Post Myocardial Infarction Study New Zealand Clinical Cohort 1994-2001 ACS 1057 91.1 963  8.56 (3.58) 62.8 (10.56) 78 12771003 
POPular  The POPular study Netherlands Clinical Cohort 2005-2007 Mixed  1024 98.2 1006 1.00 (0) 63.8 (10.39) 74.6 20179285 
POPular Genetics The POPular GENETICS Study Netherlands 
& Belgium 
RCT 2011-2017 ACS 2481 94.3 2287 1.00 (0) NA 74.9 24952855 
PROSPER Prospective Study of Pravastatin in the Elderly at 
Risk 
Netherlands RCT 1997-1999 CAD 893 100.0 893  3.15 (0.71) 75.4 (3.38) 70.3 10569329 
RISCA Recurrance and Inflammation in the Acute 
Coronary Syndromes Study 
Canada Clinical Cohort 2001-2002 ACS  1054 100.0 1054  1.22 (0.18) 61.8 (11.45) 75.9 18549920 
SHEEP Stockholm Heart Epidemiology Program (SHEEP) Sweden Clinical Cohort 1992-1995 ACS 1150 100.0 1150 14.87 (5.91) 59.3 (7.21) 70.7 17667644 
SMART Second Manifestations of Arterial Disease Netherlands Clinical Cohort 1999-2010 Mixed  3057 98.2 3001  6.77 (3.86) 60.5 (9.31) 81.7 10468526 
STABILITY Stabilization of Atherosclerotic Plaque by Initiation 
of Darapladib Therapy trial 
International RCT  2008-2010 CAD 10786 86.1 9287  3.60 (0.57) 64.7 (9.10) 82 24678955 
THI Texgen  USA Clinical Cohort 2001-2008 ACS 3875 73.1 2834  5.50 (3.42) 63.6 (10.61) 74.9 21414601 
TNT Treating to New Targets Canada RCT 1998-1999 CAD 10000 94.1 9409  4.36 (1.47) 61.1 (8.82) 81.6 15755765 
TRIUMPH Translational Research Investigating Underlying 
Disparities in Acute Myocardial Infarction Patient's 
Health Status 
USA Clinical Cohort 2005-2008 ACS 2062 100.0 2062  0.97 (0.15) 59.8 (12.10) 72.2 21772003 
UCORBIO Utrecht Coronary Biobank Netherlands Clinical Cohort 2011-2014 Mixed  1493 72.4 1081 1.6 (0.9) 65.4 (10.27) 75.6 NA 
UCP Utrecht Cardiovascular Pharacogenetics Study Netherlands Clinical Cohort 1985-2010 Mixed  1508 100.0 1508  8.00 (4.16) 64.1 (9.97) 75.4 25652526 
UKB UK Biobank UK Population 2006-2010 CAD 12045 94.2 11342  6.39 (1.72) 69.9 (6.07) 80.6 1001779 
VHS Verona Heart Study Italy Clinical Cohort 1996- CAD 939 100.0 939  5.62 (2.97) 61.3 (9.74) 81 10984565 
VIVIT Vorarlberg Institute for Vascular Investigation and 
Treatment (VIVIT) Study 
Austria Clinical Cohort 1999-2008 CAD 1447 99.8 1444  7.43 (2.91) 64.5 (10.45) 72 24265174 
WARSAW ACS Warsaw ACS Genetic Registry Poland Clinical Cohort 2008-2011 ACS 681 100.0 681  2.97 (1.16) 63.5 (11.84) 74.2 NA 
WTCC WTCCC CAD Study UK Clinical Cohort 1998-2003 Mixed  1926 100.0 1926 10.05 (2.81) 60.0 (8.13) 79.3 16380912, 
17634449 
 
Alias denotes the abbreviated name of study used in figures and analyses; ACS = acute coronary syndrome, CAD = coronary artery disease; PubMed IDs are provided for individual study descriptions; 
mean (standard deviation) with proportions (%) are provided unless otherwise stated. 
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Table 2: Participant characteristics of each study contributing to GENIUS-CHD. 
 
ALIAS BMI, 
kg/m2 
(SD) 
Systolic 
BP (SD) 
Diastolic BP 
(SD) 
Diabetes 
(%) 
Current 
Smoking 
(%) 
Total 
cholesterol 
(SD), mmol/L 
LDL-C 
(SD), 
mmol/L 
HDL-C (SD), 
mmol/L 
Creatinine 
(SD) 
Statin 
use (%) 
Prior 
Revasc 
(%) 
Prior MI 
(%) 
4C 30.2 (5.7) 133.8 (23) 77.9 (12.2) 21.8 19.1 4.64 (1.10) NA 1.309 (0.42) 98.7 (81) 24.7 20.6 14.1 
AGNES 26.6 (3.9) NA NA 7.9 61.0 5.26 (1.04) 3.25 (1.01) 1.198 (0.45) NA 10.0 0.0 0.0 
ANGES 28.1 (4.4) NA NA 30.8 14.7 4.71 (0.84) 2.68 (0.77) 1.166 (0.33) 83.0 (37) 69.4 42.4 24.7 
ATVB 26.8 (4.0) 132.4 (21) 83.5 (13.5) 8.2 79.5 5.83 (1.39) NA 1.080 (0.33) NA 55.4 NA NA 
CABGenomics 29.8 (5.6) NA NA 9.0 10.3 4.32 (0.94) 2.13 (0.85) 1.085 (0.35) NA 74.1 NA 37.0 
CARDIOLINES 26.9 (3.8) 134.4 (23) 84.34 (14.6) NA 0.6 5.43 (1.1) 3.84 (1.0) 1.16 (0.3) 73.09 (15) NA NA NA 
CDCS 27.3 (4.7) 129.1 (22) 74.6 (11.7) 15.2 5.8 5.01 (1.09) 2.95 (1.03) 1.175 (0.34) 100.8 (41) 46.0 26.5 30.4 
COGEN NA NA NA 16.7 26.2 NA NA NA NA NA NA NA 
COROGENE 27.6 (4.8) NA NA 18.2 34.4 4.58 (0.99) 2.43 (0.88) 1.250 (0.37) 84.0 (46) 5.2 NA NA 
CTMM 27.6 (4.4) 135.5 (19) 77.4 (11.2) 21.0 20.9 4.54 (1.06) 2.59 (0.98) 1.135 (0.32) 86.2 (40) NA NA 30.3 
CURE 27.7 (4.5) 135.1 (22) 77.1 (13.6) 20.9 23.0 NA NA NA 93.1 (35) NA 14.8 31.7 
EGCUT 29.0 (5.2) 135.7 (18) 80.4 (10.6) 18.9 19.8 5.70 (1.17) 3.84 (1.08) 1.340 (0.35) NA 27.7 15.4 35.3 
EMORY 29.8 (6.7) 137.0 (22) 75.0 (15.0) 34.2 7.8 4.49 (1.04) 2.42 (0.93) 1.090 (0.34) 100.2 (56) 74.2 59.6 26.8 
ERICO 27.0 (5.1) 134.8 (32) 99.4 (38.0) 39.4 31.2 NA NA NA NA 23.8 11.7 26.2 
FASTMI2005 27.2 (4.8) 139.9 (28) 80.0 (17.0) 35.9 29.1 5.03 (1.22) 3.03 (1.07) 1.239 (0.43) 103.4 (62) 74.1 NA 18.2 
FINCAVAS 27.8 (4.3) 140.2 (22) 82.2 (10.6) 18.4 24.3 4.70 (0.90) 2.62 (0.80) 1.300 (0.39) 90.8 (70) 57.3 32.6 39.0 
FRISCII 26.8 (3.9) 143.4 (23) 82.0 (10.6) 12.8 27.0 5.81 (1.12) 3.72 (0.99) 1.151 (0.36) 90.6 (19) 12.3 12.1 27.2 
GENDEMIP 28.6 (4.7) 137.1 (21) 84.0 (10.8) 19.0 61.0 5.42 (1.16) 3.58 (1.09) 1.183 (0.33) NA 16.7 30.2 40.8 
GENEBANK 29.4 (5.4) 132.7 (21) 75.0 (12.0) 11.8 16.8 4.38 (0.93) 2.51 (0.82) 0.903 (0.26) NA 71.8 65.3 56.1 
GENESIS-PRAXY 29.5 (6.5) 139.5 (27) 86.2 (17.2) 13.9 44.2 4.87 (1.19) 2.89 (1.13) 0.966 (0.30) 75.9 (20) 92.9 11.4 11.5 
GENOCOR NA 129.5 (20) 75.4 (11.1) 13.3 64.4 4.82 (0.92) 3.10 (0.83) 1.082 (0.28) 94.8 (27) 72.1 13.7 63.2 
GEVAMI 27.2 (4.3) 124.8 (18) 73.2 (11.1) 8.9 52.4 NA NA NA NA 13.4 0.0 0.0 
GoDARTSincident 29.8 (5.6) 126.7 (17) NA 70.9 NA 4.57 (1.02) 2.43 (0.91) 1.277 (0.41) 107.0 (65) 49.6 0.2 1.2 
GoDARTSprevalent 30.2 (5.4) 136.0 (20) NA 75.8 14.5 4.37 (0.84) 2.04 (0.74) 1.320 (0.38) 101.0 (34) 66.3 30.2 46.8 
GRACE_B 27.0 (4.3) 138.3 (25) 78.7 (14.6) 81.1 49.3 5.19 (1.20) 3.06 (1.09) 1.343 (0.98) 102.6 (63) 79.4 NA 80.5 
GRACE_UK 27.9 (5.0) 137.9 (27) 76.4 (16.5) 13.9 69.2 5.20 (1.27) 3.07 (1.14) 1.204 (0.49) 101.5 (38) 14.5 20.2 30.0 
IDEAL 27.3 (3.8) 136.9 (20) 80.4 (10.2) 11.9 20.7 5.09 (1.00) 3.14 (0.90) 1.192 (0.31) 100.6 (17) 75.5 40.9 100.0 
INTERMOUNTAIN 29.5 (6.1) 141.8 (24) 81.1 (13.3) 20.3 10.2 4.91 (1.12) 2.76 (0.94) 1.048 (0.35) 99.6 (67) 38.7 NA 6.6 
INVEST 29.4 (5.6) 148.4 (18) 82.4 (10.5) 24.3 13.3 NA NA NA NA 52.7 48.1 23.3 
JUMC 26.3 (4.5) 148.2 (25) 80.3 (12.4) 36.1 27.5 4.97 (1.08) 3.11 (1.14) 1.232 (0.37) 91.3 (42) 87.5 49.8 39.9 
KAROLA 26.9 (3.3) 120.0 (16) 73.1 (9.1) 18.6 31.8 4.44 (0.84) 2.61 (0.76) 1.030 (0.28) 82.7 (28) 77.0 42.8 22.4 
LIFE-Heart 28.9 (4.7) 139.0 (22) 80.0 (12.9) 33.9 27.8 5.16 (1.19) 3.12 (1.05) 1.227 (0.35) 88.8 (34) 45.8 NA 13.3 
LURIC 27.5 (4.0) 142.2 (24) 81.0 (11.5) 44.1 24.6 4.94 (0.99) 2.98 (0.89) 0.965 (0.26) 88.7 (38) 58.9 48.3 57.8 
MDCS 25.8 (4.0) 141.1 (20) 85.6 (10.0) 4.4 26.6 6.17 (1.1) 4.16 (1.0) 1.38 (0.4) 84.76 (16) 0.03 0.00 0.00 
NE_POLAND 24.8 (3.8) 138.7 (27) 88.1 (15.6) 22.3 48.5 5.12 (1.04) 3.31 (0.97) 1.126 (0.34) 92.0 (36) 81.2 1.7 11.2 
NEAPOLIS 28.0 (4.2) 129.4 (14) 75.7 (7.7) 42.7 26.9 4.49 (1.03) 2.45 (0.99) 1.233 (0.66) 101.0 (68) 82.6 41.9 40.9 
OHGS 28.5 (4.9) 132.2 (19) 72.1 (11.3) 5.5 19.3 5.57 (1.05) 3.46 (0.88) 1.222 (0.34) 89.1 (21) 91.6 27.8 23.3 
PERGENE 27.5 (3.5) 136.9 (15) 81.8 (8.1) 12.7 14.7 5.41 (1.04) NA NA 86.5 (26) 55.3 54.6 65.4 
PLATO 28.2 (4.5) 135.6 (22) 79.5 (12.9) 22.8 35.2 5.40 (1.23) 3.27 (1.11) 1.279 (0.35) 85.6 (26) 79.7 15.1 20.6 
PMI 26.5 (3.8) 116.5 (16) 66.5 (9.6) 12.5 28.0 5.97 (1.19) 3.98 (1.07) NA 88.0 (28) 44.6 NA 18.4 
POPular  27.2 (4.1) 144.9 (22) 81.4 (12.1) 19.0 27.6 4.56 (0.94) 2.73 (1.15) 1.260 (0.32) 92.7 (27) 80.7 32.9 43.6 
POPular Genetics NA NA NA NA NA NA NA NA NA NA NA NA 
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ALIAS BMI, 
kg/m2 
(SD) 
Systolic 
BP (SD) 
Diastolic BP 
(SD) 
Diabetes 
(%) 
Current 
Smoking 
(%) 
Total 
cholesterol 
(SD), mmol/L 
LDL-C 
(SD), 
mmol/L 
HDL-C (SD), 
mmol/L 
Creatinine 
(SD) 
Statin 
use (%) 
Prior 
Revasc 
(%) 
Prior MI 
(%) 
PROSPER 26.6 (3.9) 150.0 (22) 81.1 (11.4) 10.4 17.3 5.55 (0.84) 3.74 (0.74) 1.174 (0.31) 109.2 (23) 0.0 26.5 86.9 
RISCA 27.2 (4.4) NA NA 19.8 30.4 NA NA NA 100.6 (29) 46.6 28.3 27.8 
SHEEP 26.8 (4.0) 131.8 (21) 79.6 (10.3) 18.2 50.1 6.20 (1.16) 4.22 (1.01) 1.082 (0.31) NA 0.0 0.0 0.0 
SMART 27.4 (3.7) 137.0 (19) 80.1 (10.8) 17.1 24.2 4.66 (0.95) 2.64 (0.88) 1.231 (0.72) 92.3 (23) 77.5 100.0 44.5 
STABILITY 29.9 (5.0) 131.7 (16) 79.1 (10.0) 38.4 21.4 NA 2.25 (0.85) 1.216 (0.32) NA 97.3 74.6 58.6 
THI 29.6 (5.6) NA NA 30.4 21.1 NA NA NA NA 57.2 21.7 16.7 
TNT 28.5 (4.5) 130.7 (17) 77.9 (9.4) 14.2 13.3 4.53 (0.61) 2.52 (0.45) 1.223 (0.28) 104.5 (17) 70.1 NA 58.2 
TRIUMPH 29.6 (6.0) 117.7 (18) 68.1 (10.9) 29.1 37.4 NA 2.70 (1.02) 1.037 (0.33) 113.7 (81) 89.0 27.2 18.5 
UCORBIO 27.2 (4.3) NA NA 21.4 23.1 4.80 (1.18) 2.64 (1.05) 1.205 (0.33) 92.0 (45) 63.9 NA 29.0 
UCP NA 153.4 (25) 87.1 (13.3) NA NA 5.66 (1.10) 3.36 (1.01) 1.244 (0.33) 94.7 (25) 27.0 NA NA 
UKB 29.4 (4.9) 139.1 (20) 78.7 (10.9) 22.2 75.9 NA NA NA NA 82.9 59.6 36.7 
VHS 26.8 (3.6) NA NA 18.4 69.1 5.51 (1.13) 3.69 (1.00) 1.175 (0.30) 96.7 (32) 46.4 17.6 59.4 
VIVIT 27.4 (4.1) 137.4 (19) 80.6 (10.9) 31.0 19.4 5.36 (1.15) 3.33 (1.02) 1.348 (0.40) 89.9 (41) 49.9 20.6 30.4 
WARSAW ACS 28.1 (4.7) 128.0 (23) 76.2 (13.2) 21.8 42.4 4.98 (1.06) 2.99 (1.02) 1.105 (0.33) 93.5 (44) NA NA 18.9 
WTCC 27.6 (4.2) 143.6 (22) 84.3 (12.3) 11.7 12.8 5.31 (0.98) 3.12 (0.90) 1.198 (0.38) NA 71.6 67.2 72.0 
 
Data were collected through a federated analysis. Alias denotes the abbreviated name of study used in figures and analyses; BMI = body mass index; BP = blood 
pressure; LDL-C = low density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; MI = myocardial infarction; mean (standard deviation) 
and proportions (%) are provided unless otherwise stated. 
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Figure Legends 
 
Figure 1: Overview of the GENIUS-CHD consortium, illustrating inclusion criteria and 
governance structure. Following project approval by the steering committee, analyses scripts are 
prepared and distributed to all members, with sharing of summary level outputs before meta-
analysis at the coordinating centres. CHD = coronary heart disease; QC = quality control.  
Further details can be found at www.genius-chd.org 
 
Figure 2: Figure illustrating empirical power for detecting different effect sizes for biomarker 
variance and clinical events for both alpha 0.05 and 0.0001, by varying minor allele frequencies, 
for a conservative total N of 150,000 with an event rate of 10%. MAF = minor allele frequency; 
OR = odds ratio  
 
Figure 3: Meta analyses of the associations between age (per 5-year intervals) and different 
endpoints, adjusted for sex. Estimates are presented as hazard ratios (HRs) with 95% confidence 
intervals (95% CI). CHD = coronary heart disease; CVD = cardiovascular disease; MI = 
myocardial infarction.  
 
Figure 4: Meta analyses of the associations between male sex and different endpoints, adjusted 
for age.  Estimates are presented as hazard ratios (HRs) with 95% confidence intervals (95% CI). 
CHD = coronary heart disease; CVD = cardiovascular disease; MI = myocardial infarction. 
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Figure 5: Meta analyses for the associations between smoking at CHD indexing event compared 
to not smoking and for different endpoints, adjusted for age and sex. Estimates are presented as 
hazard ratios (HRs) with 95% confidence intervals (95% CI). CHD = coronary heart disease; 
CVD = cardiovascular disease; MI = myocardial infarction. 
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